Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hypertrophic cardiomyopathy (gHCM) caused by haploinsufficient myosin binding protein C3 (MYBPC3) gene mutations; and TN-301, a small molecule inhibitor of histone deacetylase 6 (HDAC6i) for use in heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM). It is also developing TN-401, an AAV-based gene therapy that addresses genetic arrhythmogenic right ventricular cardiomyopathy (gARVC) caused by plakophilin 2 (PKP2) gene mutations; an AAV-based gene therapy designed to deliver the dwarf open reading frame (DWORF) gene in the heart for DCM; and Reprogramming program, an AAV-based approach for cardiac regeneration to replace heart cells lost in patients experiencing heart failure due to prior myocardial infarction. The company was incorporated in 2016 and is headquartered in South San Francisco, California.

Tenaya Therapeutics, Inc.

Tenaya Therapeutics is a clinical stage biotechnology company. The Company was founded in 2016 by leading cardiovascular scientists from the David J. Gladstone Institutes and the University of Texas Southwestern Medical Center.

We are a biotechnology company committed to a bold mission: to discover, design, develop and deliver curative therapies that address the underlying drivers of heart disease. Our vision is to change the treatment paradigm for heart disease, and in doing so improve and extend the lives of millions of individuals and families fighting this debilitating disease. We are advancing a pipeline of disease-modifying therapies developed using our product platforms and core internal capabilities to target defined sub-populations of patients with rare or highly prevalent forms of heart disease.

The Column Group

Casdin Capital

Greenspring Associates

RTW Investments

Fidelity Management and Research Company

Google Ventures

T. Rowe Price

RA Capital Management

Tenaya Therapeutics

Wishing safe and happy holidays to our team, our partners, our friends and families and the entire Tenaya community. See you in the new year!

Pioneering the field of genetic medicines for heart disease requires some serious creativity in addition to scientific chops, and this month our Cardiovascular Genetics team showed off their fun side with a mustache-growing contest. Looking good, team. We can't wait to see what you'll do next!

Along with our partners at the DCM Foundation, Tenayans Wendy Borsari, Senior Manager of Patient Advocacy, and Jeff Haroldson, Executive Director of Medical Affairs, will present an informative webinar about genetics, gene therapies and clinical trials for cardiomyopathy today, Dec. 13 from 6:00-7:00 PM ET. 
  
Register here: bit.ly/3QMFCC0  
  
#heartdisease #PatientsFirst #GeneTherapy

Every year before the holidays, we add notes of appreciation to our Tenaya Tree of Thankfulness and watch it grow with the kind words of gratitude we share for each other. This year, we built on our tradition and got together for a special Friendsgiving potluck lunch too. We're thankful to be #OneTenaya!

Today, Tenaya CEO Faraz Ali will participate in a fireside chat at the 35th Annual Piper Sandler Healthcare Conference. Read our press release for more details: https://bit.ly/47OHlxx

Team Tenaya came together in celebration of Diwali, the festival of lights, this month. Our gathering was filled with laughter, good food and great company. Check out these photos of the team! #YouLead #Community #OneTenaya

Curious about the role of gene therapy in cardiomyopathy? We’re partnering with the DCM Foundation to present an informative webinar about genetics, gene therapies and clinical trials for cardiomyopathy on Wednesday, Dec. 13 from 6:00-7:00 PM ET.
 
Wendy Borsari, Senior Manager of Patient Advocacy, and Jeff Haroldson, Executive Director of Medical Affairs, from Tenaya will speak to a range of topics and our hopes for the future of gene therapies for the heart. Click here to register and learn more: bit.ly/3QMFCC0
 
#heartdisease #PatientsFirst #GeneTherapy

Happy Genetic Counselor Awareness Day! Tenaya recognizes the important work genetic counselors do in clinics, labs, hospitals and research to help people better understand their health, make informed healthcare decisions, and shape the future of personalized medicine. Learn more about genetic counselors: https://bit.ly/3Bi7yo8

Yesterday, we announced our Q3 earnings and business highlights - including the receipt of Fast Track designation for TN-401. See below for the top headlines! Read the full press release: https://bit.ly/3ua1mA9 #heartdisease #biotechnews

The latest #OneTenaya G&A #teambuilder brought the group to The Walt Disney Family Museum in San Francisco. The team learned that the journey from the creation of Disney to what it is today holds many parallels to the #biotech industry – there are setbacks, but a common vision and perseverance prevails. 

Thank you to the Museum for hosting us!

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue
cost of revenue	1.99M -	2.48M 24.84%	4.03M 62.10%	8.71M 116.47%	8.69M 0.30%
gross profit	-1.99M -	-2.48M 24.84%	-4.03M 62.10%	-8.71M 116.47%	-8.69M 0.30%
selling and marketing expenses					-8.69M -
general and administrative expenses	4.56M -	7.81M 71.19%	18.41M 135.67%	31.08M 68.82%	33.16M 6.66%
selling general and administrative expenses	4.56M -	7.81M 71.19%	18.41M 135.67%	31.08M 68.82%	24.47M 21.28%
research and development expenses	23.15M -	31.10M 34.35%	54.39M 74.90%	94.54M 73.80%	98.04M 3.70%
other expenses	1.03M -	430K 58.17%	-23K 105.35%	2K 108.70%
cost and expenses	27.71M -	38.91M 40.42%	72.81M 87.10%	125.62M 72.54%	131.19M 4.44%
operating expenses	27.71M -	38.91M 40.42%	72.81M 87.10%	125.62M 72.54%	122.51M 2.48%
interest expense				-1.96K -
ebitda	-25.72M -	-36.43M 41.62%	-72.81M 99.86%	-125.62M 72.54%	-122.51M 2.48%
operating income	-27.71M -	-38.91M 40.42%	-72.81M 87.10%	-125.62M 72.54%	-131.19M 4.44%
depreciation and amortization	1.99M -	2.48M 24.84%	2.96M 19.25%	6.47M 118.41%	8.69M 34.33%
total other income expenses net	1.48M -	517K 65.09%	85K 83.56%	1.96M 2,201.18%	7.11M 263.45%
income before tax	-26.23M -	-38.40M 46.37%	-72.72M 89.40%	-123.67M 70.05%	-124.08M 0.34%
income tax expense	-453K -	-87K 80.79%	-3.07M 3,427.59%	-1.96K 99.94%
net income	-25.78M -	-38.31M 48.61%	-69.65M 81.82%	-123.66M 77.54%	-124.08M 0.34%
weighted average shs out	41.12M -	41.12M 0%	41.29M 0.41%	44.82M 8.55%	73.79M 64.61%
weighted average shs out dil	41.12M -	41.12M 0%	41.29M 0.41%	44.82M 8.55%	73.79M 64.61%
eps	-0.63 -	-0.93 47.62%	-1.69 81.72%	-2.76 63.31%	-1.68 39.13%
epsdiluted	-0.63 -	-0.93 47.62%	-1.69 81.72%	-2.76 63.31%	-1.68 39.13%

NASDAQ:TNYA

Tenaya Therapeutics

Last Close

2.77

30/08 20:00

Market Cap

241.05M

Beta: -

Volume Today

257.84K

Avg: 560.72K

PE Ratio

−2.55

PFCF: −2.80

Preview